What is CVE-2026-123218?
IBM Aspera Faspex 5.0.0 through 5.0.19 could allow an authorized user to craft a specific message to bypass user authorization and gain full administrative privileges.
The record classifies CVE-2026-123218 under weakness class CWE-863. Its CVSS v3 base vector states that the flaw is reachable remotely over the network, needs no prior authentication, needs no user interaction, and has high impact on confidentiality, integrity, availability. 1 affected-product entry is recorded, across 1 vendor, listed below. The identifier was first published 2 days ago.
Severity and exploitation probability
- CVSS v3.1 base score
- 9.8 — CRITICAL
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H - EPSS (FIRST)
- 0.3% probability of exploitation in the next 30 days, higher than 34.1% of all scored CVEs
- CISA KEV
- Not listed in the CISA Known Exploited Vulnerabilities catalog
- Threadlinqs priority
- 6.3/10 — a Threadlinqs composite of the CVSS base score, the EPSS percentile and public exploit availability
- Published
- 2026-11-07
Is CVE-2026-123218 being exploited?
It currently carries a trending score of 43 in the Threadlinqs vulnerability feed.
Affected products and versions
- IBM: Aspera Faspex
How to fix CVE-2026-123218
Patch reference: https://www.ibm.com/support/pages/node/7295921. Apply the vendor fix referenced above to every affected product listed in this record, then confirm the running version against the vendor advisory.
Threat activity tracking CVE-2026-123218
No threat campaign in the Threadlinqs corpus currently references CVE-2026-123218, in its CVE list or as an indicator. The linkage is recomputed from the live corpus on every daily ingest, so this section fills in as soon as a tracked campaign cites the identifier.
Sources
Enriched from CVE.org, NVD, FIRST EPSS, GitHub Security Advisories. This product uses the NVD API but is not endorsed or certified by the NVD.